Alimera Sciences Inc
NASDAQ:ALIM

Watchlist Manager
Alimera Sciences Inc Logo
Alimera Sciences Inc
NASDAQ:ALIM
Watchlist
Price: 5.54 USD -0.18%
Market Cap: $301.3m

Operating Margin

0.2%
Current
Improving
by 10.1%
vs 3-y average of -9.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0.2%
=
Operating Income
$199k
/
Revenue
$99.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0.2%
=
Operating Income
$199k
/
Revenue
$99.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Alimera Sciences Inc
NASDAQ:ALIM
290.2m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.9B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.5B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
36th
Based on 14 112 companies
36th percentile
0.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Alimera Sciences Inc
Glance View

Market Cap
301.3m USD
Industry
Pharmaceuticals

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 145 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The firm focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The firm commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

ALIM Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
0.2%
=
Operating Income
$199k
/
Revenue
$99.7m
What is Alimera Sciences Inc's current Operating Margin?

The current Operating Margin for Alimera Sciences Inc is 0.2%, which is above its 3-year median of -9.9%.

How has Operating Margin changed over time?

Over the last 3 years, Alimera Sciences Inc’s Operating Margin has decreased from 8.7% to 0.2%. During this period, it reached a low of -22.7% on Sep 30, 2022 and a high of 8.7% on May 30, 2021.

Back to Top